Last Updated: 08/05/2026

LinkGevity

Cambridge

Founded 2023

AI-driven drug discovery targeting necrosis and age-related disease

LinkGevity is a preclinical-stage biotechnology company developing anti-necrotic therapeutics for age-related and degenerative diseases.

Founded in 2023 and based at Babraham Research Campus, the company's proprietary Blueprint Theory of Ageing identifies necrosis as a key driver of biological decline, informing its AI-enabled drug discovery platform.

Its lead programme targets kidney disease, with broader applications across age-related conditions.

Biotech Drug Discovery AI & Machine Learning

Ageing & Longevity Nephrology Small Molecule Drugs

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of

Babraham Research Campus BioIndustry Association

Similar Companies

LCC Technologies

Liverpool

LabGenius Therapeutics

London

Recursion

Oxford